Antibody Light-Induced Selectivity Enhancement

Grant Agreement ID
H2020-EU.1.3.3. – Stimulating innovation by means of cross-fertilisation of knowledge
Call reference
Implementation period
01.03.2021. – 28.02.2025.
Project coordinator
ENAMINE Ltd (Ukraine)
Project partners
University of Cambridge (UK)
Latvian Institute of Organic Synthesis (Latvia)
Karlsruhe Institute of Technology (Germany)
National Cancer Institute of Ukraine (Ukraine)
Cancer Center Amsterdam (Netherlands)
Lumobiotics GmbH (Germany)
Leader of LIOS team
Prof. Aigars Jirgensons
Total Project Budget
€ 745 200

Project ALISE will integrate the expertise, resources, and knowledge of participating institutions focusing on the design, synthesis, and preclinical study of conjugates of monoclonal antibodies with peptides whose anti-cancer activity can be enhanced in tumors by irradiation with light (LC-APCs). The possibility to boost the anti-cancer activity only in tumors, multiplied by targeting cancer cells with antibodies will be a basis for innovative and safer therapeutic strategies.

Four of seven participating institutions already have successfully collaborated in the field of light-controllable anticancer peptides, but this Project will widen the scope of collaboration, both in terms of the research field and collaborating institutions.

The participating institutions are complementary in their expertise and know-how: the University of Cambridge will contribute with its know-how in the design and preparation of antibodies. Light controllable peptides will be designed at Latvian Institute of Organic Synthesis and Karlsruhe Institute of Technology, synthesized, then loaded onto the antibodies in Cambridge. Company Enamine will perform an initial screening of the conjugates in vitro and assess their safety. National Cancer Institute of Ukraine will contribute with its expertise in immunology, Cancer Center Amsterdam – with its expertise and knowledge in preclinical and clinical oncology. Lumobiotics GmbH will complement the consortium with its expertise in drug development.

Integration of this potential will be achieved through research staff exchange and other activities organized in five work packages:

  1. design and synthesis of novel light-controllable peptides as anti-cancer antibody payloads
  2. preparation and characterization of peptide conjugates with a model antibody
  3. biological screening of model LC-APCs
  4. preclinical evaluation of the LC-APCs aiming at treatment of human PDAC
  5. management, training, communication, dissemination.